Cogent Biosciences, Inc. (COGT)
After hours:
| Previous close | 8.01 |
| Open | 8.13 |
| Bid | 8.37 x 400 |
| Ask | 8.42 x 200 |
| Day's range | 7.98 - 8.46 |
| 52-week range | 3.67 - 13.50 |
| Volume | |
| Avg. volume | 1,387,361 |
| Market cap | 801.24M |
| Beta (5Y monthly) | -0.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.49 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.70 |
GlobeNewswireCogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and lead
- GlobeNewswire
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
Bezuclastinib + sunitinib combination therapy reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior treatment Encouraging long-term safety and tolerability with combination bezuclastinib and sunitinib therapy in Part 1 PEAK Phase 3 guidance accelerated with enrollment completion now expected in 3Q 2024 Company announces new advanced GIST clinical trial sponsored by the Sarcoma Alliance for Research through Collaboration (SAR
Simply Wall St.We Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
